English
This article is from Journal of Pharmacology & Pharmacotherapeutics , volume 5 . Abstract Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability.
Sign in with your free account to read, download EPUBs or listen.
Ebook · Delamanid: A new armor in combating drug-resistant tuberculosis. · Xavier, Alphienes Stanley, Lakshmanan, Mageshwaran · Internet Archive